TD Asset Management
CCCC icon

TD Asset Management’s C4 Therapeutics CCCC Stock Holding History

TD Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,400
Closed -$256K – 1283
2024
Q3 		$256K Buy
+43,400
New +$261K ﹤0.01% 1351
2024
Q2 		– Sell
-92,800
Closed -$758K – 1377
2024
Q1 		$758K Sell
92,800
-1,600
-2% -$12.4K ﹤0.01% 1227
2023
Q4 		$533K Buy
+94,400
New +$215K ﹤0.01% 1291
2023
Q3 		– Sell
-48,453
Closed -$133K – 1418
2023
Q2 		$133K Hold
48,453
– – ﹤0.01% 1381
2023
Q1 		$152K Hold
48,453
– – ﹤0.01% 1391
2022
Q4 		$286K Hold
48,453
– – ﹤0.01% 1364
2022
Q3 		$414K Sell
48,453
-6,700
-12% -$69.6K ﹤0.01% 1327
2022
Q2 		$416K Sell
55,153
-52,000
-49% -$458K ﹤0.01% 1318
2022
Q1 		$2.6M Buy
107,153
+800
+0.8% +$19.4K ﹤0.01% 1005
2021
Q4 		$3.42M Buy
106,353
+6,600
+7% +$261K ﹤0.01% 980
2021
Q3 		$4.46M Buy
99,753
+3,900
+4% +$167K ﹤0.01% 846
2021
Q2 		$4.13M Buy
95,853
+29,300
+44% +$1.05M ﹤0.01% 880
2021
Q1 		$2.46M Buy
66,553
+50,772
+322% +$2.02M ﹤0.01% 1056
2020
Q4 		$523K Buy
+15,781
New +$458K ﹤0.01% 1326

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TD Asset Management's CCCC Position: Q4 2024 in Review

TD Asset Management sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 43,400 shares — an estimated $256K sold.

TD Asset Management first reported a position in CCCC in Q4 2020 and held it in 14 quarters. The position peaked at $4.46M in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • TD Asset Management reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • TD Asset Management sold 43,400 C4 Therapeutics shares in Q4 2024, an estimated $256K.
  • TD Asset Management first reported a position in C4 Therapeutics in Q4 2020 and held it in 14 quarters.
  • TD Asset Management's C4 Therapeutics position peaked at $4.46M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on TD Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.